Loading
Non Small Cell Carcinoma / PF-08046054 / Non Small Cell Lung Carcinoma · Phase 3 Trial
ClinicalTrials.gov · August 17, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 3 randomized controlled trial comparing the investigational agent PF-08046054/SGN-PDL1V against docetaxel monotherapy in previously treated, PD-L1-positive NSCLC with prior progression on checkpoint inhibitors and/or chemotherapy. The study is actively recruiting and has not yet reported results.
Phase 3, Interventional, Randomized, Parallel, Open label, Treatment purpose. Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma; age from 18 Years. Intervention: PF-08046054 monotherapy. Compared with: Docetaxel monotherapy — Active Comparator. n = 680. 425 sites across 29 countries.
This is a Phase 3 randomized controlled trial comparing the investigational agent PF-08046054/SGN-PDL1V against docetaxel monotherapy in previously treated, PD-L1-positive NSCLC with prior progression on checkpoint inhibitors and/or chemotherapy. The study is actively recruiting and has not yet reported results.
This is a registry record with no posted efficacy, safety, or outcome data; results cannot be assessed. No baseline characteristics, safety signals, or interim analyses are available.
The source did not state who this applies to in practice.
This is a recruiting Phase 3 RCT with no posted results; the registry record describes study design and planned enrollment only, making it impossible to assess efficacy or safety.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07144280). This is a study registration, not published results. Lead sponsor: Pfizer. Recruitment status: RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 680 participants (ESTIMATED). Conditions: Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma. Interventions: DRUG: PF-08046054; DRUG: Docetaxel monotherapy. Primary outcome measures: Overall Survival , Approximately 5 years. Brief summary: The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cancer progression during or after treatment with PD-L1 or PD-1 inhibitors, platinum-based chemotherapy, and targeted treatment regimen(s) for participants with known actionable genomic alterations (AGAs). Participants in this study must have cancer that has spread through their body or can't be removed with surgery or treated with definitive radiation. Participants will randomly (like a flip of the coin) be assigned to either the PF-08046054 treatment group or the docetaxel treatment group. Participants in the PF-08046054 treatment group will receive an IV infusion (injected directly into the veins) twice during each 21-day cycle. Participants in the docetaxel treatment group will receive an IV infusion once during each 21-day cycle. Study participation may be up to 5 years if the participant's NSCLC is responding to treatment. The study team will see how each participant is doing with the study treatment during regular visits at the clinic.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.